What's Happening?
Molecular Instruments has announced the release of HCR Gold IF on the BOND RX research staining instrument, developed by Leica Biosystems. This new offering aims to enhance automated multiplex immunofluorescence workflows, allowing researchers to move
from tissue samples to biological insights more efficiently. The HCR Gold IF enables flexible multiplex protein detection using off-the-shelf primary antibodies, supporting multiple primary antibodies from the same host species and isotype without disrupting established workflows. The assay is powered by the HCR HiFi Encoder, which facilitates higher-plex protein analysis while preserving existing antibody portfolios and prior validation work. This development is part of Molecular Instruments' broader vision to provide HCR-powered imaging approaches that generate richer biological insights from valuable samples.
Why It's Important?
The introduction of HCR Gold IF represents a significant advancement in the field of tissue research, particularly in spatial biology and translational research applications. By enabling more flexible and reproducible multiplex protein detection, this technology supports research teams in generating reliable insights from tissue specimens. The integration of this assay into the BOND RX platform offers researchers the convenience of an established automated staining system, enhancing throughput and consistency. This development is crucial for advancing cancer diagnostics and improving lives, aligning with Leica Biosystems' mission. The ability to conduct higher-plex analysis without disrupting workflows is expected to benefit academic research, drug development, synthetic biology, and clinical pathology.
What's Next?
As Molecular Instruments continues to expand its portfolio of HCR imaging solutions, the release of HCR Gold IF is likely to drive further innovations in multiplex immunofluorescence. Researchers can anticipate more scalable and reproducible approaches that fit seamlessly into existing workflows, potentially leading to new discoveries in cancer diagnostics and other areas of medical research. The collaboration between Molecular Instruments and Leica Biosystems may also result in additional advancements in automated tissue research technologies, further enhancing the capabilities of research teams working with valuable tissue samples.
